Skip to content
Open access

AgeX trials of extending the breast screening age range: study protocol for the follow-up phase (2025–2033)

Oct 2026 · Trials · 0 citations

TL;DR

AgeX will reliably assess the clinical- and cost-effectiveness of extending breast screening to younger and/or older women, and will inform future screening policy in the UK and in countries with similar screening programmes.

Abstract

In England, the NHS breast screening programme routinely invites women aged 50–70 years for triennial digital mammography. While screening may reduce breast cancer mortality, it may also lead to overdiagnosis and unnecessary treatment. In 2007, the UK Government announced an eventual extension of the screening age range to 47–73 years, but the balance of benefits and harms outside the existing age range was uncertain. To address this, AgeX began in 2009 and comprises two large cluster-randomised trials evaluating the effects of one additional breast screening in women aged 47–49 years and, separately, in women aged 71–73 years. Between 2009 and 2020, approximately 2.8 million younger women and 1.7 million older women were randomised to be offered, or not offered, one additional screening invitation. Long-term follow-up continues through electronic linkage to routinely collected NHS records. The primary analyses are of breast cancer mortality, and main subsidiary analyses are of breast cancer incidence, treatment and health economic evaluation. The population for analyses will be restricted to approximately 2 million younger women and 1 million older women who, at randomisation, were of eligible age, alive, linkable to national records, without any history in national records of cancer or breast disease, and likely to accept screening based on previous attendance. All exclusions are unbiased, as they are based on information recorded before randomisation. Adherence-corrected analyses will estimate the effects of attending one additional screening at age 47–49 and, separately, at age 71–73. Parallel intention-to-treat analyses will assess the effects of being invited, irrespective of attendance. Analyses of incidence and treatment are planned for 2026. Interim analyses of breast cancer mortality (follow-up to December 2026) are planned for 2027–2028, with final analyses (follow-up to December 2031) in 2032–2033. Health economic analyses will accompany the final mortality results. AgeX will reliably assess the clinical- and cost-effectiveness of extending breast screening to younger and/or older women, and will inform future screening policy in the UK and in countries with similar screening programmes. ClinicalTrials.gov NCT01081288. Registered on 04/03/2010; UK Clinical Study Registry ISRCTN33292440. Registered on 22/02/2010.

Read PDF

Similar papers

Review Open access 2026

Effectiveness of mammographic screening for reducing breast cancer mortality in women aged 40 to 49 years

Mammographic screening in women aged 40–49 years was associated with a significant decrease in breast cancer mortality, and the findings suggest potential benefits and support consideration of screening expansion to this population.

Nícolas Marques Barros, Igor Diniz Alves, Walter Johnatha dos Santos Pereira et al. · 0 citations
Open access Oct 2026

Baseline prevalence of lung cancer screening and associated factors among women in breast cancer screening clinics prior to the Pink & Pearl program: A retrospective analysis of electronic health records

The need for strategies to improve smoking history documentation and promote tobacco cessation efforts in cancer screening programs is highlighted and the Pink & Pearl program, a co-located breast and lung cancer screening initiative at these sites, will be evaluated.

B. Odeny, Sri Gopalsamy Ramaswamy, Benjamin Bowe et al. · 0 citations
Open access 2026

Breast cancer diagnosis outside the screening age range: an analysis of nearly 400,000 cases in the oncology panel

Introduction: The perceived increase in breast cancer among young women conflicts with Brazilian policies. While the Ministry of Health (MS) traditionally recommends screening from age 50 — with a recent deliberation allowing individualized screening for ages 40–49 — the Brazilian Society of Mastology (SBM) advocates s...

Mirella Laranjeira Nunes, Luan Fernandes Lins, Deborah de Albuquerque Beltrão Amorim et al. · 0 citations
Open access Oct 2026

Mammographic screening effectiveness in reducing breast cancer mortality in Sicily, Italy, 2008–2023

Abstract Background Breast cancer is the leading cause of cancer death among women globally. In Italy, approximately 55,900 new cases and 15,500 deaths were recorded in 2022–2023. In Sicily, mammographic screening (MS) adherence persistently falls below national and European targets, creating a health equity gap. In de...

M. LaBella, S. Scondotto, W. P. Addario et al. · 0 citations
Open access 2026

Mammography coverage and breast cancer in Roraima from 2020 to 2024

The increase in mortality associated with reduced screening coverage suggests low adherence to early detection and possible inefficiencies in local public health policies.

Antonio Railman Oliveira Gouvêa · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.